Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) is projected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Seres Therapeutics to post earnings of ($0.17) per share for the quarter.

Seres Therapeutics Trading Up 14.1 %

Shares of MCRB stock opened at $0.76 on Thursday. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $1.53. The firm’s 50 day moving average is $0.82 and its 200-day moving average is $0.84. The firm has a market capitalization of $130.60 million, a price-to-earnings ratio of -3.33 and a beta of 2.11.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Thursday, November 14th. StockNews.com lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th. Finally, Chardan Capital reiterated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.